Literature DB >> 25156166

Myocardial performance index derived from pre-ejection period as a novel and useful predictor of cardiovascular events in atrial fibrillation.

Chun-Yuan Chu1, Wen-Hsien Lee2, Po-Chao Hsu3, Hung-Hao Lee1, Cheng-An Chiu1, Ho-Ming Su4, Tsung-Hsien Lin3, Chee-Siong Lee3, Hsueh-Wei Yen3, Wen-Chol Voon3, Wen-Ter Lai3, Sheng-Hsiung Sheu3.   

Abstract

PURPOSE: The pre-ejection period-derived myocardial performance index measured from tissue Doppler echocardiography (PEPa-derived MPI) was reported to be associated with left ventricular systolic and diastolic function in atrial fibrillation (AF). However, its relationship with cardiovascular outcomes in AF has never been evaluated. This study sought to examine the ability of PEPa-derived MPI in predicting adverse cardiovascular events in AF patients.
METHODS: In 196 persistent AF patients, we performed comprehensive echocardiography with measurement of PEPa-derived MPI using index beat method. The index beat was defined as the beat following the nearly equal preceding (RR1) and pre-preceding (RR2) intervals. The cycle length of index beat and RR1 and RR2 must be >500ms and the difference between RR1 and RR2 must be <60ms. Cardiovascular events were defined as cardiovascular death, nonfatal stroke, and hospitalization for heart failure.
RESULTS: In the multivariate analysis, chronic heart failure and increased ratio of transmitral E-wave velocity to early diastolic mitral annulus velocity (E/Ea) and PEPa-derived MPI (per 0.1 increase, hazard ratio, 1.104; 95% confidence interval, 1.032-1.182, p=0.004) were associated with increased cardiovascular events. The addition of PEPa-derived MPI to a Cox model containing chronic heart failure, systolic blood pressure, age, diabetes, prior stroke, left ventricular ejection fraction, and E/Ea provided an additional benefit in prediction of adverse cardiovascular events (p=0.015).
CONCLUSIONS: In AF patients, the PEPa-derived MPI was a useful predictor of adverse cardiovascular events and could offer an additional prognostic benefit over conventional clinical and echocardiographic parameters.
Copyright © 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Ejection time; Isovolumic relaxation time; Myocardial performance index; Pre-ejection period

Mesh:

Year:  2014        PMID: 25156166     DOI: 10.1016/j.jjcc.2014.07.014

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  5 in total

1.  Predictors for non-delayed discharge after transcatheter aortic valve replacement: utility of echocardiographic parameters.

Authors:  Tomoo Nagai; Hitomi Horinouchi; Yohei Ohno; Tsutomu Murakami; Katsuaki Sakai; Gaku Nakazawa; Koichiro Yoshioka; Yuji Ikari
Journal:  Int J Cardiovasc Imaging       Date:  2020-07-25       Impact factor: 2.357

Review 2.  Clinical Relevance of the Spectral Tissue Doppler E/e' Ratio in the Management of Patients with Atrial Fibrillation: a Comprehensive Review of the Literature.

Authors:  Stephane Arques
Journal:  J Atr Fibrillation       Date:  2018-08-31

3.  Improvement of the myocardial performance index in atrial fibrilation patients treated with amiodarone after cardioversion.

Authors:  Feyzullah Besli; Cengiz Basar; Mesut Kecebas; Yasin Turker
Journal:  J Interv Card Electrophysiol       Date:  2015-01-16       Impact factor: 1.900

4.  Systolic time intervals derived from electrocardiographic gated intra-renal artery Doppler waveform associated with left ventricular systolic function.

Authors:  Wen-Hsien Lee; Po-Chao Hsu; Chun-Yuan Chu; Szu-Chia Chen; Hung-Hao Lee; Meng-Kuang Lee; Chee-Siong Lee; Hsueh-Wei Yen; Tsung-Hsien Lin; Wen-Chol Voon; Wen-Ter Lai; Sheng-Hsiung Sheu; Ho-Ming Su
Journal:  Sci Rep       Date:  2016-08-24       Impact factor: 4.379

5.  Relationship Between Tei Index and PEP-Derived Myocardial Performance Index in Sinus Rhythm.

Authors:  Feyzullah Besli; Cengiz Basar; Ismail Ekinozu; Yasin Turker
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.